tiprankstipranks
Trending News
More News >

CSPC Pharmaceutical Partners with Cipla USA for U.S. Market Expansion

Story Highlights
CSPC Pharmaceutical Partners with Cipla USA for U.S. Market Expansion

Don’t Miss TipRanks’ Half-Year Sale

CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.

CSPC Pharmaceutical Group Limited has entered into an exclusive license agreement with Cipla USA, Inc. for the commercialization of its Irinotecan Liposome Injection in the United States. This agreement includes an upfront payment of $15 million to CSPC, with potential milestone payments and royalties based on sales. This strategic partnership is expected to enhance CSPC’s market presence in the U.S. and potentially increase its revenue through milestone and royalty payments.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company utilizes a liposome technology platform to create products such as the Irinotecan Liposome Injection, which is used in the treatment of various solid tumors.

Average Trading Volume: 144,611,316

Technical Sentiment Signal: Hold

Current Market Cap: HK$63.24B

Learn more about 1093 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1